Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this phase I trial is to evaluate the toxicity and feasibility of a tumor-specific RNA-NP vaccine in patients with stage IIB-IV melanoma who have evidence of progressive disease by RECIST 1.1 criteria while receiving adjuvant aPD1 therapy, or those who progress within 6 months of completion of adjuvant treatment, or unresectable stage II soft tissue sarcoma or stage III-IV soft tissue sarcoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Ogólny stan zdrowia pozwalający na aktywność przynajmniej na połowę czasu
- •Wystarczająca ilość czerwonych krwinek, płytek krwi i białych krwinek
- •Prawidłowe funkcje wątroby i nerek
- •Nowotwór dostępny do pobrania próbki do badań
- •Tylko jeden aktywny nowotwór w momencie rozpoczęcia badania
- •Pisemna zgoda na udział w badaniu
- •Stosowanie antykoncepcji przez osoby zdolne do reprodukcji (przez 4 miesiące po ostatniej dawce)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 99 Years
- Last updated (source)
- July 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Florida
Gainesville, United States
Trial contact
Brittany Lansford
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.